A61K 31/4166
Having oxo groups directly attached to the heterocyclic ring
Official title: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K31/4166 (Having oxo groups directly attached to the heterocyclic ring) appears on 602 US grants and 1,172 published applications in this corpus.
Search patents in A61K- Granted patents
- 602
- Published applications
- 1,172
- Assignees
- 539
- Inventors
- 2,116
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 4 | 0 |
| 1996 | 2 | 0 |
| 1997 | 4 | 0 |
| 1998 | 5 | 0 |
| 1999 | 6 | 0 |
| 2000 | 13 | 0 |
| 2001 | 3 | 1 |
| 2002 | 7 | 10 |
| 2003 | 5 | 14 |
| 2004 | 5 | 15 |
| 2005 | 4 | 18 |
| 2006 | 0 | 36 |
| 2007 | 5 | 20 |
| 2008 | 6 | 24 |
| 2009 | 8 | 32 |
| 2010 | 13 | 29 |
| 2011 | 9 | 32 |
| 2012 | 17 | 35 |
| 2013 | 19 | 33 |
| 2014 | 26 | 63 |
| 2015 | 35 | 63 |
| 2016 | 32 | 74 |
| 2017 | 37 | 60 |
| 2018 | 47 | 62 |
| 2019 | 37 | 80 |
| 2020 | 51 | 72 |
| 2021 | 37 | 88 |
| 2022 | 38 | 81 |
| 2023 | 35 | 64 |
| 2024 | 34 | 68 |
| 2025 | 28 | 59 |
| 2026 | 29 | 39 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods comprising endothelin a receptor antagonists and androgen therapies29 Sep 2026US 12,746,239 B2The United States Government as represented by the Department of Veterans Affairs
- TEAD inhibitors29 Sep 2026US 12,747,207 B2Orion Corporation
- Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities22 Sep 2026US 12,740,992 B2Jazz Pharmaceuticals Research UK Limited
- Pharmaceutical composition comprising enzalutamide8 Sep 2026US 12,728,096 B2Synthon BV
- Daclatasvir for use in treating lung and prostate cancer1 Sep 2026US 12,721,838 B2Henry Ford Health System
- Lysine acetyltransferase 6a (kat6a) inhibitor, combinations and uses thereof1 Oct 2026US 2026/0294884 A1Insilico Medicine IP Limited
- Testosterone and difluoromethylornithine combination therapy for prostate cancer24 Sep 2026US 2026/0284076 A1The Johns Hopkins University
- A biphasic liquid pharmaceutical composition of an anticonvulsant drug and the process of preparing the same17 Sep 2026US 2026/0272832 A1Orbit Pharma Limited
- Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer3 Sep 2026US 2026/0256742 A1
- Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c8 substrates3 Sep 2026US 2026/0256759 A1Corcept Therapeutics, Inc.
Most cited
By later US patents
- Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction140US 6,037,346 AVivus, Inc. · 2000
- Cyclodextrins as suspending agents for pharmaceutical suspensions98US 5,576,311 APharmos Corporation · 1996
- Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction85US 6,127,363 AVivus, Inc. · 2000
- Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems79US 7,589,057 B2Allergan, Inc. · 2009
- Use of cannabinoids in the treatment of epilepsy78US 9,474,726 B2GW Pharma Limited · 2016